In vivo expression of antimicrobial peptides in atopic dermatitis

Maja-Lisa Clausen; Hans-Christian Slotved; Karen A. Krogfelt; Paal Skytt Andersen; Tove Agner

doi:10.1111/exd.12831

In vivo expression of antimicrobial peptides in atopic dermatitis

Maja-Lisa Clausen, Hans-Christian Slotved, Karen A. Krogfelt, Paal Skytt Andersen, Tove Agner

16 Citations (Scopus)

Abstract

The aim of this review is to present findings on expression of antimicrobial peptides (AMPs) in atopic dermatitis (AD) skin, focusing only on in vivo studies, and to discuss differences in results obtained using various skin sampling techniques and different methodology for analysis of AMPs. The review also includes a discussion of the effect of frequently used treatments on AMP expression. Many studies have shown a reduced level of AMPs in lesional AD skin when compared to psoriatic skin, explaining the high frequency of AD-related infections. Interestingly, however, non-lesional AD skin has shown the same upregulation of AMPs after barrier disruption as non-lesional psoriatic skin. Various methods have been used to analyse AMP expression in the skin, and when comparing these methods, differences are revealed in AMP expression depending on the method used for sampling and analysis. Comparisons indicate that analyses of mRNA levels of AMPs may find greater differences in expression than analyses of protein levels. Few studies evaluate the effect of topical treatments on the expression of AMPs, and these indicate an inhibition of AMP expression, particularly after use of corticosteroids. AMPs are important components of the skin as a defense against infections, and despite much research, the clinical importance of the effect of common treatments, including systemic treatments for AD and the interplay between AMPs and the skin microbiome, is still largely unknown.

Original language	English
Journal	Experimental Dermatology
Volume	25
Issue number	1
Pages (from-to)	3-9
ISSN	0906-6705
DOIs	https://doi.org/10.1111/exd.12831
Publication status	Published - 1 Jan 2016

Keywords

AD
AMP
antimicrobial peptides
atopic dermatitis

Access to Document

10.1111/exd.12831

exd.12831Final published version, 380 KB

Cite this

@article{7797867148cd41e6895b0687e1e2a390,

title = "In vivo expression of antimicrobial peptides in atopic dermatitis",

abstract = "The aim of this review is to present findings on expression of antimicrobial peptides (AMPs) in atopic dermatitis (AD) skin, focusing only on in vivo studies, and to discuss differences in results obtained using various skin sampling techniques and different methodology for analysis of AMPs. The review also includes a discussion of the effect of frequently used treatments on AMP expression. Many studies have shown a reduced level of AMPs in lesional AD skin when compared to psoriatic skin, explaining the high frequency of AD-related infections. Interestingly, however, non-lesional AD skin has shown the same upregulation of AMPs after barrier disruption as non-lesional psoriatic skin. Various methods have been used to analyse AMP expression in the skin, and when comparing these methods, differences are revealed in AMP expression depending on the method used for sampling and analysis. Comparisons indicate that analyses of mRNA levels of AMPs may find greater differences in expression than analyses of protein levels. Few studies evaluate the effect of topical treatments on the expression of AMPs, and these indicate an inhibition of AMP expression, particularly after use of corticosteroids. AMPs are important components of the skin as a defense against infections, and despite much research, the clinical importance of the effect of common treatments, including systemic treatments for AD and the interplay between AMPs and the skin microbiome, is still largely unknown.",

keywords = "AD, AMP, antimicrobial peptides, atopic dermatitis",

author = "Maja-Lisa Clausen and Hans-Christian Slotved and Krogfelt, {Karen A.} and Andersen, {Paal Skytt} and Tove Agner",

year = "2016",

month = jan,

day = "1",

doi = "10.1111/exd.12831",

language = "English",

volume = "25",

pages = "3--9",

journal = "Experimental Dermatology",

issn = "0906-6705",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - In vivo expression of antimicrobial peptides in atopic dermatitis

AU - Clausen, Maja-Lisa

AU - Slotved, Hans-Christian

AU - Krogfelt, Karen A.

AU - Andersen, Paal Skytt

AU - Agner, Tove

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The aim of this review is to present findings on expression of antimicrobial peptides (AMPs) in atopic dermatitis (AD) skin, focusing only on in vivo studies, and to discuss differences in results obtained using various skin sampling techniques and different methodology for analysis of AMPs. The review also includes a discussion of the effect of frequently used treatments on AMP expression. Many studies have shown a reduced level of AMPs in lesional AD skin when compared to psoriatic skin, explaining the high frequency of AD-related infections. Interestingly, however, non-lesional AD skin has shown the same upregulation of AMPs after barrier disruption as non-lesional psoriatic skin. Various methods have been used to analyse AMP expression in the skin, and when comparing these methods, differences are revealed in AMP expression depending on the method used for sampling and analysis. Comparisons indicate that analyses of mRNA levels of AMPs may find greater differences in expression than analyses of protein levels. Few studies evaluate the effect of topical treatments on the expression of AMPs, and these indicate an inhibition of AMP expression, particularly after use of corticosteroids. AMPs are important components of the skin as a defense against infections, and despite much research, the clinical importance of the effect of common treatments, including systemic treatments for AD and the interplay between AMPs and the skin microbiome, is still largely unknown.

AB - The aim of this review is to present findings on expression of antimicrobial peptides (AMPs) in atopic dermatitis (AD) skin, focusing only on in vivo studies, and to discuss differences in results obtained using various skin sampling techniques and different methodology for analysis of AMPs. The review also includes a discussion of the effect of frequently used treatments on AMP expression. Many studies have shown a reduced level of AMPs in lesional AD skin when compared to psoriatic skin, explaining the high frequency of AD-related infections. Interestingly, however, non-lesional AD skin has shown the same upregulation of AMPs after barrier disruption as non-lesional psoriatic skin. Various methods have been used to analyse AMP expression in the skin, and when comparing these methods, differences are revealed in AMP expression depending on the method used for sampling and analysis. Comparisons indicate that analyses of mRNA levels of AMPs may find greater differences in expression than analyses of protein levels. Few studies evaluate the effect of topical treatments on the expression of AMPs, and these indicate an inhibition of AMP expression, particularly after use of corticosteroids. AMPs are important components of the skin as a defense against infections, and despite much research, the clinical importance of the effect of common treatments, including systemic treatments for AD and the interplay between AMPs and the skin microbiome, is still largely unknown.

KW - AD

KW - AMP

KW - antimicrobial peptides

KW - atopic dermatitis

U2 - 10.1111/exd.12831

DO - 10.1111/exd.12831

M3 - Journal article

C2 - 26269388

SN - 0906-6705

VL - 25

SP - 3

EP - 9

JO - Experimental Dermatology

JF - Experimental Dermatology

IS - 1

ER -